CAMBRIDGE, Mass., Aug. 25, 2022 -- Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced...
Arthur Klausner will be a panelist at the New York Biotechnology Association's Annual Meeting
News | 04. 17. 2006
